Partner Therapeutics, Inc. (PTx)
Partner Therapeutics, Inc. (PTx) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer and other serious diseases. With a strong foundation in oncology, PTx also leads research in infectious diseases, immunology, and urgent clinical needs such as COVID-19 and sepsis. The company integrates research, manufacturing, development, and commercialization to rapidly bring therapies to patients worldwide, emphasizing collaboration with medical and scientific communities to improve patient outcomes and quality of life. PTx's mission-driven approach is supported by a leadership team with deep industry experience and a commitment to advancing late-stage therapeutics that address significant unmet medical needs. The company also maintains a robust compliance program in accordance with state and federal regulations.
What We Do
A yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), LEUKINE is FDA-approved for multiple indications including neutrophil recovery in AML, mobilization of hematopoietic progenitor cells, acceleration of myeloid reconstitution post-transplant, treatment of delayed neutrophil recovery, and increasing survival after myelosuppressive radiation exposure (H-ARS). It is also approved in Japan (as Sargmalin) for autoimmune pulmonary alveolar proteinosis (aPAP) and is under investigation for additional uses such as COVID-19 associated respiratory illness, sepsis, and neurodegenerative diseases.
BIZENGRI is the first and only FDA-approved therapy for pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) with NRG1 gene fusions that are advanced, unresectable, or metastatic. Partner Therapeutics has a license agreement for U.S. commercialization of zenocutuzumab for NRG1 fusion-positive cancers. The Wholesale Acquisition Cost (WAC) for BIZENGRI is $23,750 for a 2-vial pack (375mg/18.75mL), as of January 1, 2025.
IMREPLYS is the same formulation as LEUKINE, recommended for EU approval to treat patients of all ages acutely exposed to myelosuppressive doses of radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome).
FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability, and inflammation. Potential applications include COVID-19, pandemic, chemical, biological, radiological, and nuclear threats. PTx is developing FX-06 in partnership with SIRS Therapeutics and F4 Pharma.
Regenerative Medicine
Digital Health Technologies
Services
Key People
Chief Business Officer (President, Health Security and Critical Care)
Chief Development Officer
Co-founder, Board of Directors
Co-founder, Chief Medical Officer, Board of Directors
Board of Directors
Board of Directors
News & Updates
LEUKINE received FDA approval for the treatment of adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, H-ARS).
The FDA granted orphan drug designation to LEUKINE for the potential treatment of Stage IIb-IV melanoma.
LEUKINE received FDA orphan drug designation for the treatment of pulmonary alveolar proteinosis (PAP).
Tanner Pharma Group signed a distribution agreement to provide LEUKINE in areas outside the U.S. and Canada where the product is not yet registered.
PTx acquired global rights to develop, manufacture, and commercialize LEUKINE from Sanofi, including the Lynnwood, WA Biologics Manufacturing Facility.
PTx closed a $60 million Series A financing to support pipeline development and commercial operations.